FBR & Co reaffirmed their outperform rating on shares of Rexahn Pharmaceuticals, Inc. (NYSE:RNN) in a research report sent to investors on Thursday. FBR & Co currently has a $3.00 target price on the stock.
Separately, Zacks Investment Research raised Rexahn Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, July 13th.
Shares of Rexahn Pharmaceuticals (NYSE:RNN) traded down 2.6417% during midday trading on Thursday, reaching $0.1769. The company’s stock had a trading volume of 1,288,611 shares. The stock has a 50 day moving average price of $0.23 and a 200-day moving average price of $0.27. Rexahn Pharmaceuticals has a 52-week low of $0.17 and a 52-week high of $0.52. The company’s market capitalization is $37.73 million.
Rexahn Pharmaceuticals (NYSE:RNN) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.01) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.01. Equities research analysts expect that Rexahn Pharmaceuticals will post ($0.07) EPS for the current year.
An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Vanguard Group Inc. raised its stake in Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned about 2.30% of Rexahn Pharmaceuticals worth $1,232,000 as of its most recent filing with the SEC.
Rexahn Pharmaceuticals Company Profile